Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes

• Published in: The New England journal of medicine Vol. 389; no. 23; pp. 2151 - 2161
• Main Authors: Ramos, Eleanor L., Dayan, Colin M., Chatenoud, Lucienne, Sumnik, Zdenek, Simmons, Kimber M., Szypowska, Agnieszka, Gitelman, Stephen E., Knecht, Laura A., Niemoeller, Elisabeth, Tian, Wei, Herold, Kevan C.
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 07.12.2023
• Subjects: Adolescence; Adolescent; Adolescents; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Beta cells; C-Peptide - analysis; Caregivers; CD3 antigen; CD3 Complex - antagonists & inhibitors; CD3 Complex - immunology; Child; Coronaviruses; COVID-19; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - diagnosis; Diabetes Mellitus, Type 1 - immunology; Diabetes Mellitus, Type 1 - therapy; Disease Progression; Double-Blind Method; Drug administration; Drug dosages; Glucose monitoring; Hemoglobin; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - therapeutic use; Insulin; Insulin - administration & dosage; Insulin - therapeutic use; Insulin-Secreting Cells - drug effects; Insulin-Secreting Cells - immunology; Lymphocytes T; Lymphopenia; Monoclonal antibodies; Pandemics; Patients; Pediatrics; Peptides; Placebos; Preservation; Remission (Medicine); T-Lymphocytes - drug effects; T-Lymphocytes - immunology; Teenagers

Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage 2) disease. Whether treatment with intravenous teplizumab in patients wi...